{"id":"darunavir-ritonavir-qd-raltegravir-bid","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Insomnia"},{"rate":"5-10%","effect":"Rash"},{"rate":"1-5%","effect":"Anemia"},{"rate":"1-5%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Darunavir/ritonavir QD works by inhibiting the protease enzyme of the HIV virus, preventing it from replicating. Raltegravir BID works by inhibiting the integrase enzyme of the HIV virus, also preventing it from replicating. This combination of drugs is used to treat HIV infection.","oneSentence":"Darunavir/ritonavir QD is a protease inhibitor that blocks HIV replication, while raltegravir BID is an integrase strand transfer inhibitor that also blocks HIV replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:44.004Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT03394196","phase":"NA","title":"RESIST-2: 2nd-line ART for HIV-2 Infection","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-07-04","conditions":"HIV-2 Infection","enrollment":152},{"nctId":"NCT01258374","phase":"","title":"Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2010-05","conditions":"Integrase Inhibitors, HIV; HIV PROTEASE INHIB","enrollment":15},{"nctId":"NCT00830804","phase":"PHASE2","title":"Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-04","conditions":"HIV-1 Infections","enrollment":113},{"nctId":"NCT01294761","phase":"NA","title":"Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir","status":"COMPLETED","sponsor":"National Center for Global Health and Medicine, Japan","startDate":"2011-02","conditions":"HIV Infections","enrollment":59},{"nctId":"NCT00525733","phase":"NA","title":"Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2007-10","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT01033760","phase":"PHASE3","title":"Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2010-04","conditions":"HIV-1 Infections","enrollment":90},{"nctId":"NCT01066962","phase":"PHASE3","title":"Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2010-08","conditions":"HIV Infections","enrollment":800},{"nctId":"NCT01066065","phase":"","title":"Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients","status":"UNKNOWN","sponsor":"Hospital Carlos III, Madrid","startDate":"2010-02","conditions":"Cardiovascular Disease, HIV Infections","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"darunavir/ritonavir QD + raltegravir BID","genericName":"darunavir/ritonavir QD + raltegravir BID","companyName":"ANRS, Emerging Infectious Diseases","companyId":"anrs-emerging-infectious-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Darunavir/ritonavir QD is a protease inhibitor that blocks HIV replication, while raltegravir BID is an integrase strand transfer inhibitor that also blocks HIV replication. Used for Treatment of HIV-1 infection.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}